血脂管理与中国医保  

Lipid management and Chinese medical insurance

作　　者：汪朝晖[1] 廖玉华[1] WANG Zhaohui;LIAO Yuhua(Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,china)

机构地区：[1]华中科技大学同济医学院附属协和医院心内科,武汉430022

出　　处：《临床心血管病杂志》2023年第9期661-663,共3页Journal of Clinical Cardiology

摘　　要：近期,《中国血脂管理指南(2023)》公开发表,对动脉粥样硬化性心血管疾病(ASCVD)患者的血脂管理尤其是低密度脂蛋白胆固醇(LDL-C)水平提出了更严格的目标值和更精准的分层管理策略,多种降脂药物的联合治疗是分层管理血脂达标的有效措施。多年来降脂药物主要为原研进口,价格居高不下。近5年,国家医保局通过实施药品集中带量采购、医保国谈、国谈药“双通道”等措施,使降脂药物价格大幅下降,大大提高了ASCVD患者用药的可及性,为ASCVD患者的血脂分层管理提供了重要保障。Recently,the Chinese Lipid Management Guideline(2023) was published,which proposed stricter target values and more accurate stratified management strategies for lipid management in atherosclerotic cardiovascular disease(ASCVD) patients,especially low-density lipoprotein cholesterol(LDL-C) levels.The combination treatment of multiple lipid-lowering drugs is an effective measure to reach the standard of stratified lipid management.For many years,lipid-lowering drugs are mainly imported from other countries,and their prices remain high.In the past five years,the National Medical Insurance Administration has implemented measures such as centralized drug procurement,national medical insurance negotiation,and "dual channel" of national drug negotiation,which has greatly reduced the price of lipid-lowering drugs,greatly improved the accessibility of drugs for patients with ASCVD,and provided an important guarantee for the stratified management of lipids in patients with ASCVD.

关 键 词：低密度脂蛋白胆固醇 血脂达标 分层管理 集中采购 国家谈判 

分 类 号：R54[医药卫生—心血管疾病]